CNS Pharmaceuticals Company Presentation

CNS pharmaceuticals 3 • Our lead drug candidate, Berubicin, was developed by Dr. Waldemar Priebe, Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center. • Berubicin is an Organ Targeted Therapeutic that appeared to demonstrate one durable Complete Response in a Phase 1 human clinical trial conducted by Reata Pharmaceuticals.* • We have a collaboration and asset purchase agreement with Reata Pharmaceuticals for all trial data and drug manufacturing documentation. • Over $25 million in private capital and grants were invested in Berubicin prior to our $9.8 million IPO in November 2019. • Licensed second drug candidate, WP1244 , in 1Q20. • WP1244 is a novel DNA binding agent believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. • We have a development agreement for an anti-viral portfolio with potential COVID-19 applications About Us. CNS IS DEVELOPING NOVEL ANTI-CANCER DRUG CANDIDATES FOR THE TREATMENT OF PRIMARY ANDMETASTATICBRAINCANCERANDCENTRALNERVOUS SYSTEMTUMORS. * A “complete response” to treatment means no signs of cancer are visible on MRI. This does not always mean the cancer is cured. Also called a complete remission: www.cancer.gov/publications/dictionaries/cancer-terms/def/complete-response